) The Translational Oncology Program consists of 49 Members, representing total peer-reviewed funding of $5,642,092 in annual direct costs. During the last year, its Members produced 140 cancer-relevant, peer-reviewed publications, 26% of which were intra- and inter-programmatic collaborations. Members are focused on testing the clinical validity and applicability of observations emerging from basic biological laboratories and on understanding the underlying molecular and cellular mechanisms that determine the pathogenesis, prognosis and therapeutic susceptibility of the tumor. We recognize from recent direct experience that the current strong trends toward specialization in medical practice and changes in healthcare organization in California and elsewhere can constitute a challenge to academic medicine and research. We nevertheless believe that its momentum can also be harnessed to promote expertise and quality, if one adapts speedily, flexib ly and wisely. Accordingly, we have encouraged the development of interactive clinical organ- and/or research-specific focus groups around which basic and population scientists can assemble for mutual interest and benefit. These are thriving and intellectually productive, judged by objective measures such as discoveries, publications and peer reviewed grant support. The Translational Oncology Program consists of several well-established clinical focus groups in the specific areas of breast cancer, leukemia/lymphoma, stem cell transplantation, melanoma, head and neck cancer, and pediatric oncology, and is actively implementing measures which are assisting other focus groups to realize full potential. The many strong laboratory teams and powerful analytical disciplines, such as gene therapy and molecular pathology converging here with clinical medicine are, therefore, standing on the brink of very productive and stimulating times. Together with the interactive potential of the new sh ared resources assembling in this Center, our clinical research is expected to be powerfully fruitful in the practical application of new discoveries during the next funding cycle.
| Dow, Michelle; Pyke, Rachel M; Tsui, Brian Y et al. (2018) Integrative genomic analysis of mouse and human hepatocellular carcinoma. Proc Natl Acad Sci U S A 115:E9879-E9888 |
| Que, Xuchu; Hung, Ming-Yow; Yeang, Calvin et al. (2018) Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature 558:301-306 |
| Murzin, Vyacheslav L; Woods, Kaley; Moiseenko, Vitali et al. (2018) 4? plan optimization for cortical-sparing brain radiotherapy. Radiother Oncol 127:128-135 |
| Norton, Jeffrey A; Kim, Teresa; Kim, Joseph et al. (2018) SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors. J Gastrointest Surg 22:32-42 |
| Ikeda, Sadakatsu; Tsigelny, Igor F; Skjevik, Åge A et al. (2018) Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist 23:586-593 |
| Buckley, Alexandra R; Ideker, Trey; Carter, Hannah et al. (2018) Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas. Genome Med 10:69 |
| Parish, Austin J; Nguyen, Vi; Goodman, Aaron M et al. (2018) GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. Cancer 124:4080-4089 |
| Xu, Selene; Thompson, Wesley; Ancoli-Israel, Sonia et al. (2018) Cognition, quality-of-life, and symptom clusters in breast cancer: Using Bayesian networks to elucidate complex relationships. Psychooncology 27:802-809 |
| Tao, Li; Schwab, Richard B; San Miguel, Yazmin et al. (2018) Breast Cancer Mortality in Older and Younger Breast Cancer Patients in California. Cancer Epidemiol Biomarkers Prev : |
| Sagredo, Eduardo A; Blanco, Alejandro; Sagredo, Alfredo I et al. (2018) ADAR1-mediated RNA-editing of 3'UTRs in breast cancer. Biol Res 51:36 |
Showing the most recent 10 out of 862 publications
